Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial ...

BioAge Labs, a clinical-stage biotech firm focused on obesity and metabolic disease therapies, aims to raise up to $157.5 million through its initial public offering and private placement, Bloomberg ...

Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial ...

Obesity drug developer BioAge Labs (BIOA) files for U.S. IPO to offer 7.5M shares at $17-$19 implying valution of up to $602M ...

queue amid a flurry of IPO activity in the sector, with three biotechs listing on the Nasdaq last week – Bicara Therapeutics, ...

BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking ...

Six IPOs debuted this past week, including three deals of more than $100 million. Seven IPOs submitted initial filings.

Using Crunchbase data, we ranked five of this year’s most heavily funded companies with a female CEO and founder.